VRPXVirpax Pharmaceuticals, Inc.

About Virpax Pharmaceuticals, Inc. (VRPX)

Virpax Pharmaceuticals, Inc. (VRPX) is a Biotechnology company headquartered in Berwyn, PA, United States whose shares trade over-the-counter on the Pink tier.

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.

VRPX key facts

Ticker symbol

VRPX

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Berwyn, PA, United States

Country of incorporation

US

Estimated market cap

$311.0K (as of Apr 9, 2025)

Shares outstanding

1,242,503

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with V